Synexus acquires PAREXEL and Iatro site management organizations

9 December 1999

Synexus Ltd of the UK, which claims to be Europe's largest sitemanagement organization in turnover terms, has acquired two smaller SMOs, one in Scotland and another in Wales, which means that one in six UK citizens is now covered by a Synexus center. The company's chairman, Ian Smith, said that the acquisition of PAREXEL (based in Cardiff) and Iatro of Glasgow, gives Synexus the chance "to broaden our offering to the global pharmaceutical companies for whom we work." He added that the firm can also undertake clinical trials on a much broader range of diseases than before and offer a more efficient service to shorten drug development times "than can any of our European competitors." For further information about Synexus, phone: +44 (0)1257 230723; e-mail: paul.evans@synexus.co.uk.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight